Casey discusses the potential implications of widespread obesity medication use, highlighting that nearly 80% of the U.S. population could be eligible for treatments like semaglutide. She emphasizes the staggering financial burden on taxpayers, estimating $2.2 trillion annually, and argues for a reevaluation of public health strategies. Instead of relying solely on medication, she advocates for systemic changes to improve the environment and access to healthy food for families.
